MicroPort NeuroTech Limited ((HK:2172)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MicroPort NeuroTech Limited is conducting a clinical trial titled ‘A Prospective, Multi-center, Open-label, Controlled, Superiority, Randomized, Controlled Registration Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease (TARGET-DREAM)’. The study aims to evaluate the efficacy of two types of rapamycin target-eluting stents compared to a bare-metal stent in treating symptomatic cerebral artery atherosclerotic disease. This trial is significant as it could potentially offer improved treatment options for patients with this condition.
The interventions being tested are two drug-eluting stents: Experimental Device A, a self-expanding stent, and Experimental Device B, a balloon-expandable stent. Both are designed to release rapamycin to prevent artery blockage, offering a potential advancement over traditional bare-metal stents.
The study is designed as a Phase 3, randomized, controlled trial with a parallel intervention model. It involves single masking, where the outcomes assessor is blinded. The primary purpose is to assess treatment efficacy.
The study is set to begin on March 27, 2025, with primary completion expected by April 11, 2025. These dates are crucial as they mark the start of data collection and the anticipated completion of the primary phase of the study, respectively.
This clinical update could influence MicroPort NeuroTech’s stock performance positively if the results show significant benefits of the new stents. Investors may view this as a competitive edge in the medical device market, particularly against other companies in the neurovascular space.
The study is ongoing, with further details available on the ClinicalTrials portal.